Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma
- PMID: 28279985
- PMCID: PMC5507368
- DOI: 10.3174/ajnr.A5099
Restriction Spectrum Imaging Improves Risk Stratification in Patients with Glioblastoma
Abstract
Background and purpose: ADC as a marker of tumor cellularity has been promising for evaluating the response to therapy in patients with glioblastoma but does not successfully stratify patients according to outcomes, especially in the upfront setting. Here we investigate whether restriction spectrum imaging, an advanced diffusion imaging model, performed after an operation but before radiation therapy, could improve risk stratification in patients with newly diagnosed glioblastoma relative to ADC.
Materials and methods: Pre-radiation therapy diffusion-weighted and structural imaging of 40 patients with glioblastoma were examined retrospectively. Restriction spectrum imaging and ADC-based hypercellularity volume fraction (restriction spectrum imaging-FLAIR volume fraction, restriction spectrum imaging-contrast-enhanced volume fraction, ADC-FLAIR volume fraction, ADC-contrast-enhanced volume fraction) and intensities (restriction spectrum imaging-FLAIR 90th percentile, restriction spectrum imaging-contrast-enhanced 90th percentile, ADC-FLAIR 10th percentile, ADC-contrast-enhanced 10th percentile) within the contrast-enhanced and FLAIR hyperintensity VOIs were calculated. The association of diffusion imaging metrics, contrast-enhanced volume, and FLAIR hyperintensity volume with progression-free survival and overall survival was evaluated by using Cox proportional hazards models.
Results: Among the diffusion metrics, restriction spectrum imaging-FLAIR volume fraction was the strongest prognostic metric of progression-free survival (P = .036) and overall survival (P = .007) in a multivariate Cox proportional hazards analysis, with higher values indicating earlier progression and shorter survival. Restriction spectrum imaging-FLAIR 90th percentile was also associated with overall survival (P = .043), with higher intensities, indicating shorter survival. None of the ADC metrics were associated with progression-free survival/overall survival. Contrast-enhanced volume exhibited a trend toward significance for overall survival (P = .063).
Conclusions: Restriction spectrum imaging-derived cellularity in FLAIR hyperintensity regions may be a more robust prognostic marker than ADC and conventional imaging for early progression and poorer survival in patients with glioblastoma. However, future studies with larger samples are needed to explore its predictive ability.
© 2017 by American Journal of Neuroradiology.
Figures



Similar articles
-
Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.Neuro Oncol. 2016 Nov;18(11):1579-1590. doi: 10.1093/neuonc/now063. Epub 2016 Apr 21. Neuro Oncol. 2016. PMID: 27106406 Free PMC article.
-
Longitudinal restriction spectrum imaging is resistant to pseudoresponse in patients with high-grade gliomas treated with bevacizumab.AJNR Am J Neuroradiol. 2013 Sep;34(9):1752-1757. doi: 10.3174/ajnr.A3506. Epub 2013 Apr 11. AJNR Am J Neuroradiol. 2013. PMID: 23578667 Free PMC article. Clinical Trial.
-
Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.Neuroradiol J. 2019 Aug;32(4):241-249. doi: 10.1177/1971400919847184. Epub 2019 May 8. Neuroradiol J. 2019. PMID: 31066622 Free PMC article.
-
Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas.Neuroimage Clin. 2018 Jul 5;20:51-60. doi: 10.1016/j.nicl.2018.07.001. eCollection 2018. Neuroimage Clin. 2018. PMID: 30069427 Free PMC article. Review.
-
Neuroimaging classification of progression patterns in glioblastoma: a systematic review.J Neurooncol. 2018 Aug;139(1):77-88. doi: 10.1007/s11060-018-2843-3. Epub 2018 Mar 30. J Neurooncol. 2018. PMID: 29603080
Cited by
-
Predicting Survival in Glioblastoma Patients Using Diffusion MR Imaging Metrics-A Systematic Review.Cancers (Basel). 2020 Oct 4;12(10):2858. doi: 10.3390/cancers12102858. Cancers (Basel). 2020. PMID: 33020420 Free PMC article. Review.
-
Conventional and advanced magnetic resonance imaging in patients with high-grade glioma.Q J Nucl Med Mol Imaging. 2018 Sep;62(3):239-253. doi: 10.23736/S1824-4785.18.03086-8. Epub 2018 Apr 26. Q J Nucl Med Mol Imaging. 2018. PMID: 29696946 Free PMC article. Review.
-
Imaging in neuro-oncology.Ther Adv Neurol Disord. 2018 Feb 28;11:1756286418759865. doi: 10.1177/1756286418759865. eCollection 2018. Ther Adv Neurol Disord. 2018. PMID: 29511385 Free PMC article. Review.
-
The value of restriction spectrum imaging in predicting lymph node metastases in rectal cancer: a comparative study with diffusion-weighted imaging and diffusion kurtosis imaging.Insights Imaging. 2024 Dec 19;15(1):302. doi: 10.1186/s13244-024-01852-z. Insights Imaging. 2024. PMID: 39699826 Free PMC article.
References
-
- Stupp R, Mason WP, van den Bent MJ, et al. ; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96 10.1056/NEJMoa043330 - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical